Zymeworks (ZYME) Depreciation & Amortization (CF) (2022 - 2026)
Zymeworks (ZYME) reported Depreciation & Amortization (CF) of $963000.0 for Q1 2026, down 1.83% on a YoY basis from $981000.0 in Q1 2025, and up 7.24% sequentially from $898000.0 in Q4 2025.
Zymeworks (ZYME) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Zymeworks (ZYME) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $963000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 1.83% year-over-year to $963000.0; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (down 11.12% YoY), and the FY2025 full-year result was $3.7 million, down 12.39% from the prior year.
- Depreciation & Amortization (CF) advanced to $963000.0 in Q1 2026, from $898000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.4 million in Q3 2023 to a low of $885000.0 in Q2 2025.
- A 5-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 73.36% in 2023 and tumbled 56.89% in 2024, its largest moves.
- Tracing ZYME's Depreciation & Amortization (CF) over 5 years: stood at $1.2 million in 2022, then jumped by 33.33% to $1.5 million in 2023, then slumped by 35.09% to $997000.0 in 2024, then slipped by 9.93% to $898000.0 in 2025, then grew by 7.24% to $963000.0 in 2026.
- Business Quant data shows ZYME's Depreciation & Amortization (CF) at $963000.0 in Q1 2026, $898000.0 in Q4 2025, and $905000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 963,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 963,000.00 |
| Mar 31, 2026 | 963,000.00 |
| Dec 31, 2025 | 898,000.00 |
| Dec 31, 2025 | 898,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Jun 30, 2025 | 885,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Dec 31, 2024 | 997,000.00 |
| Dec 31, 2024 | 997,000.00 |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Dec 31, 2023 | 1.54 Mn |